From the Department of Neurology (E.J.M., P.L.M., R.S., F.S.E.) and Department of Radiology (P.A.C.), Division of Neuroradiology, Harvard Medical School, Massachusetts General Hospital, Boston; Department of Pediatrics (E.J.M.), Division of Child Neurology, Weill Cornell Medical College, New York-Presbyterian Hospital, NY; and Department of Pediatric Neurology (S.v.d.S., M.E.), Emma Children's Hospital, Amsterdam University Medical Center, the Netherlands.
Neurology. 2020 Jun 16;94(24):e2499-e2507. doi: 10.1212/WNL.0000000000009626. Epub 2020 Jun 1.
To gain insight into the natural history of arrested cerebral adrenoleukodystrophy (CALD) by quantifying the change in Neurologic Function Score (NFS) and Loes Score (LS) over time in patients whose cerebral lesions spontaneously stopped progressing.
We retrospectively reviewed a series of 22 patients with arrested CALD followed longitudinally over a median time of 2.4 years (0.7-17.0 years). Primary outcomes were change in radiographic disease burden (measured by LS) and clinical symptoms (measured by NFS) between patients who never developed a contrast-enhancing lesion (gadolinium enhancement (GdE)- subgroup) and those who did (GdE+ subgroup). Secondary analyses comparing patterns of neuroanatomic involvement and lesion number, and prevalence estimates, were performed.
Cerebral lesions were first detected at a median age of 23.3 years (8.0-67.6 years) with an initial LS of 4 (0.5-9). NFS was 0.5 (0-6). Overall change in NFS or LS per year did not differ between subgroups. No patients who remained GdE- converted to a progressive CALD phenotype. The presence of contrast enhancement was associated with disease progression ( = 0.559, < 0.001). Four patients (18.2%) underwent step-wise progression, followed by spontaneous resolution of contrast enhancement and rearrest of disease. Three patients (13.6%) converted to progressive CALD. Nineteen patients (86.4%) had arrested CALD at the most recent follow-up. The prevalence of arrested CALD is 12.4%.
Arrested CALD lesions can begin in childhood, and patients are often asymptomatic early in disease. The majority of patients remain stable. However, clinical and MRI surveillance is recommended because a minority of patients undergo step-wise progression or conversion to progressive CALD.
通过量化自发停止进展的脑肾上腺脑白质营养不良(CALD)患者的神经功能评分(NFS)和 Loes 评分(LS)随时间的变化,深入了解其自然病史。
我们回顾性分析了 22 例经长期随访(中位数时间为 2.4 年,范围为 0.7-17.0 年)的自发停止进展的 CALD 患者系列。主要结局指标是从未出现对比增强病变(钆增强(GdE)亚组)和出现对比增强病变(GdE+亚组)的患者之间,放射学疾病负担(LS 测量)和临床症状(NFS 测量)的变化。还进行了比较神经解剖学受累模式和病变数量的次要分析,并进行了患病率估计。
脑病变最初在中位数年龄 23.3 岁(8.0-67.6 岁)时被发现,初始 LS 为 4(0.5-9)。NFS 为 0.5(0-6)。亚组之间,NFS 或 LS 每年的变化无差异。未发生 GdE-的患者转变为进展性 CALD 表型。对比增强的存在与疾病进展相关( = 0.559,<0.001)。4 例(18.2%)患者进行了逐步进展,随后对比增强自发消退,疾病再次停止。3 例(13.6%)患者转为进展性 CALD。19 例(86.4%)患者在最近的随访中仍患有 CALD。CALD 停止进展的患病率为 12.4%。
CALD 病变可始于儿童期,且患者在疾病早期通常无症状。大多数患者保持稳定。然而,建议进行临床和 MRI 监测,因为少数患者会发生逐步进展或转为进展性 CALD。